CA3249181A1 - POLYPEPTIDE ANALOGUES DERIVED FROM ANNEXIN A1 - Google Patents

POLYPEPTIDE ANALOGUES DERIVED FROM ANNEXIN A1

Info

Publication number
CA3249181A1
CA3249181A1 CA3249181A CA3249181A CA3249181A1 CA 3249181 A1 CA3249181 A1 CA 3249181A1 CA 3249181 A CA3249181 A CA 3249181A CA 3249181 A CA3249181 A CA 3249181A CA 3249181 A1 CA3249181 A1 CA 3249181A1
Authority
CA
Canada
Prior art keywords
lys
seq
polypeptide
amino acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3249181A
Other languages
English (en)
French (fr)
Inventor
Thomas Engelbrecht Nordkild Jonassen
Original Assignee
Resother Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resother Pharma AS filed Critical Resother Pharma AS
Publication of CA3249181A1 publication Critical patent/CA3249181A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3249181A 2022-02-23 2023-02-23 POLYPEPTIDE ANALOGUES DERIVED FROM ANNEXIN A1 Pending CA3249181A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22158253 2022-02-23
EP22158253.9 2022-02-23
PCT/EP2023/054519 WO2023161323A1 (en) 2022-02-23 2023-02-23 Annexin a1-derived polypeptide analogues

Publications (1)

Publication Number Publication Date
CA3249181A1 true CA3249181A1 (en) 2023-08-31

Family

ID=80461005

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3249181A Pending CA3249181A1 (en) 2022-02-23 2023-02-23 POLYPEPTIDE ANALOGUES DERIVED FROM ANNEXIN A1

Country Status (7)

Country Link
US (1) US20250388632A1 (https=)
EP (1) EP4482853A1 (https=)
JP (1) JP2025506775A (https=)
CN (1) CN118891273A (https=)
AU (1) AU2023226134A1 (https=)
CA (1) CA3249181A1 (https=)
WO (1) WO2023161323A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025083393A1 (en) * 2023-10-16 2025-04-24 Therakind Limited Antimicrobial use of peptides derived from annexin a1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002364607A1 (en) * 2001-12-28 2003-07-24 The Burnham Institute Novel ligand involved in the transmigration of leukocytes .
FR2856069A1 (fr) * 2003-06-10 2004-12-17 Bionexis Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation
US9102753B2 (en) 2011-06-15 2015-08-11 Ugp Therapeutics, Inc. Anti-inflammatory pharmaceutical products
KR20150029457A (ko) * 2013-09-10 2015-03-18 삼성전자주식회사 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도
JP2017513875A (ja) 2014-04-22 2017-06-01 ティーエックスピー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 分枝状アミノ酸プローブを有するペプチド類似体

Also Published As

Publication number Publication date
AU2023226134A1 (en) 2024-08-01
EP4482853A1 (en) 2025-01-01
US20250388632A1 (en) 2025-12-25
WO2023161323A1 (en) 2023-08-31
JP2025506775A (ja) 2025-03-13
CN118891273A (zh) 2024-11-01

Similar Documents

Publication Publication Date Title
US20230295255A1 (en) Annexin a1-derived polypeptide analogues
US9951116B2 (en) Alpha- and gamma-MSH analogues
US20150297672A1 (en) Alpha- and gamma-MSH analogues
CN116421712A (zh) 一种d-构型溶瘤肽-喜树碱缀合物及其制备方法和应用
US20150376254A1 (en) Gamma-msh analogues
US20250388632A1 (en) Annexin a1-derived polypeptide analogues
WO2017068020A1 (en) W-peptide analog
JP2001226284A (ja) 神経突起誘発剤
US20230303640A1 (en) Exendin-4 peptide analogs
HK1197552B (en) Alpha- and gamma-msh analogues
EP0428700A1 (en) IRREVERSIBLE BOMBESIN ANTAGONISTS.
JPH09512787A (ja) ペプシンの放出を抑制するためのペプチド
CZ285155B6 (cs) Peptidy s organoprotektivním účinkem, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
BR112015008767B1 (pt) Peptídeo, composição farmacêutica e uso do peptídeo

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240719

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250102

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250102

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250102

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250130

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250130

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250130

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250211

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250214

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260130

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260130

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260420